Aethlon Medical, a provider in developing therapeutic filtration devices to address infectious disease and cancer, has partnered with Fabiani & Company to assist in the establishment of federal partnerships that advance biodefense, cancer and chronic infectious disease applications of the Aethlon Hemopurifier.

The Aethlon Hemopurifier is a medical device that selectively targets the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system, the company said.

Aethlon chairman and CEO Jim Joyce said that their colleagues at Fabiani & Company provide a well respected presence inside the beltway and increase likelihood of accessing non-dilutive resources to advance endeavors across multiple disease conditions in the US.

Fabiani & Company principal Stephen Conafay said that they are pleased and excited to partner with Aethlon Medical and Aethlon’s experienced management team, coupled with their Hemopurifier technology, offers to provide a wide variety of cancer and immune suppressed patients a minimally invasive therapeutic strategy at significantly reduced costs when compared to present therapies.